Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of K-912 in Japanese patients with solid tumors
jRCT2080222174Phase 1
- Sponsor
- Kowa Company, Ltd.
- Start
- Aug 2013
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanoparticle epirubicin in Nonhematologic neoplasms, sponsored by Kowa Company, Ltd.
02
Drugs
nanoparticle epirubicin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222174.